Skip to main content
. 2016 Jan 27;6:19772. doi: 10.1038/srep19772

Figure 5. Evaluation of healthy-donor specific ADCC.

Figure 5

(a) BT-474 serving as target cells were incubated overnight with PBMCs, serving as effector cells, freshly isolated from healthy volunteers. Various E:T ratios, without (white bar) or with 10 μg/mL of Trastuzumab (black bar), were employed. (b) PBMCs, freshly isolated from four healthy volunteers, were used as effector cells and were found to be capable of inducing individual ADCC activities against BT-474 as target cells, when incubated overnight without (white bar) or with 10 μg/mL of Trastuzumab (black bar) or Bevacizumab (dot bar). (c) The individual ADCC activities, determined every 1~2 months using freshly isolated PBMCs from healthy volunteers, were measured employing our flowcytometric assay with (black circles) or without (white circles) Trastuzumab. The results of the analyses of dead target cells (%) are presented as mean values ± SD for each of the experiments.